KeepHealthCare.ORG – New blood test that predict if the drug palbociclib will help breast cancer patients
Another examination has discovered a blood test for cancer DNA could anticipate if a woman is reacting to the breast cancer drug palbociclib, months sooner than current tests. The test could recognize in a little while whether the medication is working, in spite of the fact that they alert the outcomes require repeating before they are utilized clinically.
The exploration, distributed today in the journal Nature Communications, was generally funded by the MRC. The specialists tried ladies with an oestrogen receptor-positive breast cancer disease – the most widely recognized kind – who were partaking in a clinical trial of palbociclib for cutting-edge bosom tumor.
Currently, women need to wait for two-three months to find out, using a scan, if palbociclib is working.
This new test rather searches for circulating tumor DNA – fragments of DNA shed by the disease that have entered the bloodstream. The DNA mutations related to the growth can be distinguished in these examples.
The analysts found that they could foresee if the palbociclib treatment would work by looking at the measure of a quality PIK3CA recognized in a blood test before treatment and 15 days in the wake of beginning treatment. In the investigation, 73 ladies had the PIK3CA transformation and were given blood tests when beginning palbociclib treatment.
In these women, the researchers found that those who had a small decrease in PIK3CA circulating DNA at 15 days had a median progression-free survival (the length of time the patient survived and cancer did not get worse) of only 4.1 months, compared with women with a large decrease in PIK3CA, who had a median progression-free survival of 11.2 months.
The test could allow the women in the first group for whom the treatment is not as effective to be identified early and they could consider altering their treatment.
Professor Nicholas Turneropens in new window, senior author and Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “Palbociclib is one of a new class of drugs that delays cancer progression for patients with advanced breast cancer, but it’s not effective for everybody. The problem is we have to wait for two to three months before doing a scan to see if the therapy is working.”
“Our new study found that a blood test for cancer DNA in the first two weeks of treatment indicated whether the drug was likely to be effective. Having an early indication of how likely a treatment is to work might allow us to adapt treatment – switching some patients to an alternative drug that is more likely to benefit them.”
Dr Nathan Richardson, Head of Molecular and Cellular Medicine at the MRC, said: “It is exciting to see that using advances in diagnostic techniques, such as genetic tests for circulating tumour DNA, we may be able to more accurately define groups of patients and help us deliver the right treatment to the right patient sooner. This study provides early evidence that might help us understand sooner when a drug is successfully treating breast cancer, and if not, it can be discontinued and better approaches pursued.”